Clinical trial
Phase I/II, Open-Label Trial of Three Monoclonal Antibodies
NCT00219986 · Rockefeller University, Other · Completed
Key facts
| NCT number | NCT00219986 |
|---|---|
| Title | Phase I/II, Open-Label Trial of Three Monoclonal Antibodies |
| Official title | A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection |
| Lead sponsor | Rockefeller University, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Potent HAART during acute or early HIV-1 infection |
| Enrollment | 12 |
| Start date | Oct 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Jul 18, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: